- Latest available (Revised)
- Original (As adopted by EU)
Commission Regulation (EC) No 761/2009 of 23 July 2009 amending, for the purpose of its adaptation to technical progress, Regulation (EC) No 440/2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) (Text with EEA relevance)
When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.
Legislation.gov.uk publishes the UK version. EUR-Lex publishes the EU version. The EU Exit Web Archive holds a snapshot of EUR-Lex’s version from IP completion day (31 December 2020 11.00 p.m.).
This is the original version as it was originally adopted in the EU.
This legislation may since have been updated - see the latest available (revised) version
The test report should include the following information:
Test and Control Substances:
chemical name(s) such as IUPAC or CAS name and CAS number, if known,
purity and composition of the substance (in percentage(s) by weight),
physical-chemical properties relevant to the conduct of the study (e.g. physical state, stability and volatility, pH, water solubility if known),
treatment of the test/control substances prior to testing, if applicable (e.g. warming, grinding),
storage conditions.
Justification of the skin model and protocol used.
Test Conditions:
cell system used,
calibration information for measuring device, and bandpass used for measuring cell viability (e.g. spectrophotometer),
complete supporting information for the specific skin model used including its performance. This should include, but is not limited to:
viability;
barrier function;
morphology;
reproducibility and predictivity;
quality controls (QC) of the model;
details of the test procedure used,
test doses used, duration of exposure and post treatment incubation period,
description of any modifications of the test procedure,
reference to historical data of the model. This should include, but is not limited to:
acceptability of the QC data with reference to historical batch data;
acceptability of the positive and negative control values with reference to positive and negative control means and ranges,
description of evaluation criteria used including the justification for the selection of the cut-off point(s) for the prediction model.
Results:
tabulation of data from individual test samples,
description of other effects observed.
Discussion of the results.
Conclusions.
The Whole Regulation you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
The Schedules you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As adopted by EU): The original version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: